BioPharmSignal logoBioPharmSignal

Biotech News

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

MaxCyte (MXCT)MaxCyteCompany update

ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has

Related news

MXCTMaxCyte2026-07-15 20:05 EST

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

MXCTMaxCyte2026-05-12 20:06 EST

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

SRPTSarepta Therapeutics2026-07-27 12:30 EST

Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer

ABEOAbeona Therapeutics2026-08-06 11:30 EST

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

SRPTSarepta Therapeutics2026-08-05 20:05 EST

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

TSHATaysha Gene Therapies2026-08-04 20:00 EST

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

CRSPCRISPR Therapeutics2026-08-03 20:15 EST

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

NTLAIntellia2026-07-30 12:00 EST

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

SANASana Biotechnology2026-05-11 20:05 EST

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

CRSPCRISPR Therapeutics2026-05-04 20:30 EST

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

View all latest news

MaxCyte

Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instruments introduce molecules into cells at laboratory through commercial scale while preserving cell viability and function. Strategic...

Recent company news

MXCTMaxCyte2026-07-21 12:05 EST

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

MXCTMaxCyte2026-07-15 20:05 EST

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

MXCTMaxCyte2026-06-23 13:00 EST

VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering

MXCTMaxCyte2026-05-12 20:06 EST

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MXCTMaxCyte2026-04-29 20:05 EST

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

Stock data

Close
1.11 USD
Market cap
131.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States